[go: up one dir, main page]

AR069500A1 - Metodos de tratamiento de la esteatohepatitis no alcoholica (nash ) utilizando productos de cisteamina - Google Patents

Metodos de tratamiento de la esteatohepatitis no alcoholica (nash ) utilizando productos de cisteamina

Info

Publication number
AR069500A1
AR069500A1 ARP080105211A ARP080105211A AR069500A1 AR 069500 A1 AR069500 A1 AR 069500A1 AR P080105211 A ARP080105211 A AR P080105211A AR P080105211 A ARP080105211 A AR P080105211A AR 069500 A1 AR069500 A1 AR 069500A1
Authority
AR
Argentina
Prior art keywords
cellulose
phthalate
composition
acetate
alcoholic
Prior art date
Application number
ARP080105211A
Other languages
English (en)
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40679016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR069500(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California filed Critical Univ California
Publication of AR069500A1 publication Critical patent/AR069500A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Reivindicacion 1: Uso de un producto de cisteamina, para la elaboracion de un medicamento para el tratamiento de un paciente que sufre de enfermedad de hígado graso. Reivindicacion 3: Uso de una composicion que comprende cisteamina o cistamina, o una sal farmacéuticamente aceptable de las mismas, para la elaboracion de un medicamento para el tratamiento de un paciente que sufre de enfermedad de hígado graso no alcoholico (NAFLD) o de esteatohepatitis no alcoholica (NASH). Reivindicacion 12: El uso de la reivindicacion 8, en donde la forma de dosificacion de liberacion retardada o controlada comprende un recubrimiento entérico que libera la composicion de cisteamina cuando la composicion llega al intestino delgado o a una region del tracto gastrointestinal de un sujeto en el cual el pH es mayor a aproximadamente un pH de 4,5. Reivindicacion 13: El uso de la reivindicacion 12, en donde la composicion comprende un recubrimiento seleccionado del grupo integrado por laca, gelatina polimerizada, copolímero de ácido metacrílico tipo C NF, butirato ftalato de celulosa, hidrogeno ftalato de celulosa, propionato ftalato de celulosa, ftalato de polivinil acetato (PVAP), acetato ftalato de celulosa (CAP), acetato trimelitato de celulosa (CAT), ftalato de hidroxipropil metilcelulosa, acetato de hidroxipropil metilcelulosa, succinato de dioxipropil metilcelulosa, carboximetil etilcelulosa (CMEC), acetato succinato de hidroxipropil metilcelulosa (HPMCAS), y polímeros y copolímeros de ácido acrílico, normalmente formados a partir de acrilato de metilo, acrilato de etilo, metacrilato de metilo y/o metacrilato de etilo con copolímeros de ésteres de ácido acrílico y metacrílico.
ARP080105211A 2007-11-30 2008-11-28 Metodos de tratamiento de la esteatohepatitis no alcoholica (nash ) utilizando productos de cisteamina AR069500A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99151707P 2007-11-30 2007-11-30
US8539708P 2008-07-31 2008-07-31

Publications (1)

Publication Number Publication Date
AR069500A1 true AR069500A1 (es) 2010-01-27

Family

ID=40679016

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080105211A AR069500A1 (es) 2007-11-30 2008-11-28 Metodos de tratamiento de la esteatohepatitis no alcoholica (nash ) utilizando productos de cisteamina

Country Status (26)

Country Link
US (5) US7994226B2 (es)
EP (2) EP2636404B1 (es)
JP (3) JP5583022B2 (es)
KR (1) KR20100091219A (es)
CN (2) CN104825430B (es)
AR (1) AR069500A1 (es)
AU (1) AU2008329628B2 (es)
BR (1) BRPI0819690B8 (es)
CA (1) CA2706768C (es)
CL (1) CL2008003582A1 (es)
CY (1) CY1114126T1 (es)
DK (1) DK2214480T3 (es)
ES (1) ES2417179T3 (es)
HK (1) HK1141945A1 (es)
HR (1) HRP20130590T1 (es)
IL (2) IL205909B (es)
MX (2) MX2010005921A (es)
MY (1) MY156316A (es)
NZ (1) NZ585732A (es)
PL (1) PL2214480T3 (es)
PT (1) PT2214480E (es)
RU (1) RU2498795C2 (es)
SG (1) SG10201403200RA (es)
TW (2) TWI535435B (es)
WO (1) WO2009070781A1 (es)
ZA (1) ZA201003670B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8026284B2 (en) 2006-01-27 2011-09-27 The Regents Of The University Of California Enterically coated cystamine, cysteamine and derivatives thereof
AR069500A1 (es) 2007-11-30 2010-01-27 Univ California Metodos de tratamiento de la esteatohepatitis no alcoholica (nash ) utilizando productos de cisteamina
JP5800368B2 (ja) * 2010-05-19 2015-10-28 興和株式会社 非アルコール性脂肪性肝炎の予防及び／又は治療剤
AU2011263423B2 (en) * 2010-06-08 2016-10-20 Krisani Biosciences (P) Ltd Cysteamine derivatives and their use in the treatment of NASH
PL2598142T3 (pl) * 2010-07-28 2016-06-30 Orchid Chemicals And Pharmaceuticals Ltd Związki eteru difenylowego do zastosowania w leczeniu zaburzeń wątroby
WO2014045293A1 (en) * 2012-09-24 2014-03-27 Krisani Bioscience (P) Ltd. Fatty acid amides with a cysteamine or an acetylated cysteamine group and uses thereof
US20130085075A1 (en) * 2011-06-06 2013-04-04 Meso Scale Technologies, Llc Diagnostic methods for liver disorders
EP2755480B1 (en) 2011-09-16 2021-03-31 Galectin Therapeutics Inc. Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease
BR112014009789A2 (pt) * 2011-10-26 2017-04-25 Seattle Children's Res Inst cisteamina no tratamento da doença fibrótica
AU2012340670B2 (en) * 2011-11-22 2016-12-22 The Regents Of The University Of California Cysteamine and/or cystamine for treating ischemic injury
CA2869054A1 (en) * 2012-03-29 2013-10-03 Halo Therapeutics, Llc Dosage forms of halofuginone and methods of use
ES2848538T3 (es) 2012-06-06 2021-08-10 Galectin Therapeutics Inc Composiciones de galacto-ramnogalacturonato para el tratamiento de enfermedades asociadas con elevada óxido nítrico sintasa inducible
US20140314841A1 (en) 2013-04-19 2014-10-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Use of Cysteamine and Derivatives Thereof to Suppress Tumor Metastases
TWI649100B (zh) * 2013-06-17 2019-02-01 地平線罕見醫學製藥有限責任公司 延遲釋放型半胱胺珠粒調配物，以及其製備及使用方法
US9682123B2 (en) 2013-12-20 2017-06-20 The Trustees Of Columbia University In The City Of New York Methods of treating metabolic disease
RU2664696C2 (ru) * 2014-04-18 2018-08-21 ЭлДжи КЕМ, ЛТД. Композиция для предотвращения или лечения жировых болезней печени
MX2017011363A (es) * 2015-03-03 2018-03-01 Kohjin Life Sciences Co Ltd Composicion para corregir o prevenir higado graso no alcoholico.
KR20180034466A (ko) * 2015-07-02 2018-04-04 호리즌 오펀 엘엘씨 Ado-저항성 시스테아민 유사체 및 그의 용도
RU2595815C1 (ru) * 2015-07-13 2016-08-27 федеральное государственное бюджетное образовательное учреждение высшего образования "Северо-Западный государственный медицинский университет им. И.И. Мечникова" Министерства здравоохранения Российской Федерации Способ лечения больных неалкогольным стеатогепатитом на фоне метаболического синдрома
WO2017087532A1 (en) * 2015-11-16 2017-05-26 The Regents Of The University Of California Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine compounds
US10143665B2 (en) 2015-11-17 2018-12-04 Horizon Orphan Llc Methods for storing cysteamine formulations and related methods of treatment
US11173135B2 (en) 2016-03-17 2021-11-16 Thiogenesis Therapeutics, Inc. Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders
ITUA20161799A1 (it) * 2016-03-18 2017-09-18 Recordati Ind Chimica E Farmaceutica S P A Composizione farmaceutica a rilascio prolungato comprendente cisteamina o un suo sale
DK3634411T3 (da) * 2017-06-08 2023-12-04 N Gene Res Laboratories Inc Fremgangsmåder til behandling af NASH og til forebyggelse af NASH-induceret HCC
US10632092B2 (en) 2017-08-30 2020-04-28 First Fruits Business Ministry, Llc Composition for and method to increase serum adiponectin and reduce body fat
US11612576B2 (en) 2017-09-20 2023-03-28 Thiogenesis Therapeutics, Inc. Methods for the treatment of cysteamine sensitive disorders
KR102177304B1 (ko) * 2018-07-23 2020-11-10 제이투에이치바이오텍 (주) 비알콜성 지방간염의 예방 또는 치료용 약학 조성물
CN111544426A (zh) * 2019-02-12 2020-08-18 复旦大学 炔丙基半胱氨酸及其在制备新靶点药物中的用途
US20220135524A1 (en) 2019-03-26 2022-05-05 The Regents Of The University Of California Substituted amino-thiol and amino-disulfide compounds, and uses thereof
JP2022542840A (ja) * 2019-07-19 2022-10-07 フィルトリシン， インコーポレイテッド がん処置および代謝介入療法および他の使用のための組成物、方法、キットならびにシステム
CN111505099B (zh) * 2020-04-21 2023-07-04 上海市普陀区中心医院 Nash的诊断标志物及其应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110441A (en) 1974-04-29 1978-08-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Gamma-l-glutamyl cholamine phosphate
US4959306A (en) * 1986-11-28 1990-09-25 Sclavo, Inc. Labeling design for a binding assay reagent
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5639743A (en) * 1992-11-13 1997-06-17 University Of Georgia Research Foundation Compositions and methods for treating exocrine gland atrophy
JPH11302178A (ja) * 1998-02-17 1999-11-02 Otsuka Pharmaceut Factory Inc 脂肪肝予防及び治療剤
CA2236344A1 (en) * 1998-04-30 1999-10-30 Hemosol Inc. Hemoglobin-haptoglobin complexes
US20050059576A1 (en) * 1998-04-30 2005-03-17 Adamson J. Gordon Targeted delivery of antiviral compounds through hemoglobin bioconjugates
US6794414B1 (en) 1998-06-17 2004-09-21 Yeda Research And Development Co. Ltd. Method and compositions for treating diseases mediated by transglutaminase activity
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
WO2001058708A1 (en) * 2000-02-14 2001-08-16 Len Booysen Stabilizer unit
CN1144585C (zh) * 2000-12-13 2004-04-07 华扩达动物科学[I.P.2]有限公司 含有半胱胺或其盐类的促进动物快速生长的组合物及用途
US7449451B2 (en) * 2001-08-29 2008-11-11 Premier Micronutrient Corporation Use of multiple antioxidant micronutrients as systemic biological radioprotective agents against potential ionizing radiation risks
GB2379854B (en) 2001-09-19 2006-04-19 Walcom Animal Science Dairy cow feed and the use thereof
JP2005510537A (ja) * 2001-11-29 2005-04-21 サウンド・ファーマシューティカルズ・インコーポレイテッド 化学療法の所望されない効果を改善する方法および組成物
CA2825792C (en) * 2002-01-04 2016-08-16 Sound Pharmaceuticals Incorporated Otoprotectant compositions of glutathione peroxidase mimics for ameliorating hearing loss
GB2386817B (en) 2002-02-20 2006-08-23 Walcom Animal Science Feed for fish and use therof
JP2004026716A (ja) 2002-06-25 2004-01-29 Ajinomoto Co Inc ＴＮＦα産生の抑制剤
US8017651B2 (en) 2002-11-22 2011-09-13 Bionexus, Ltd. Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia
GB2398497A (en) * 2003-02-19 2004-08-25 Walcom Animal Science Composition for improving immunity of animals
JP4966665B2 (ja) * 2003-11-19 2012-07-04 オメガ バイオ−ファーマ （アイ．ピー．１） リミテッド アルコール代謝を改善し、二日酔いの影響を軽減するための材料と方法
CA2549717C (en) 2003-12-19 2012-11-13 Omega Bio-Pharma (I.P.3) Limited Compositions and methods for treating diabetes
US20050209441A1 (en) 2004-03-22 2005-09-22 Lile Jackson D Process for promoting proper folding of human serum albumin using a human serum albumin ligand
CN101822658A (zh) * 2004-05-03 2010-09-08 奥加生物药业(I.P.3)有限公司 半胱胺用于治疗高胆固醇血症和糖尿病并发症
AP2007004084A0 (en) 2005-01-05 2007-08-31 Fisher Cormack & Botha Taurine synthesis production and utility as a medicine
WO2006113914A2 (en) 2005-04-20 2006-10-26 Fred Hutchinson Cancer Research Center Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms
WO2007075702A2 (en) * 2005-12-21 2007-07-05 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and h3 receptor antagonist/inverse agonist
US20070172514A1 (en) * 2006-01-20 2007-07-26 Francis Chi Materials and methods for improving livestock productivity
US8026284B2 (en) * 2006-01-27 2011-09-27 The Regents Of The University Of California Enterically coated cystamine, cysteamine and derivatives thereof
WO2007121545A1 (en) * 2006-04-20 2007-11-01 Universidade Estadual De Campinas-Unicamp S-nitrosothiols containing compositions for the treatment of fatty liver diseases, obesity and other diseases associated with the metabolic syndrome and the use of such compositions
JP2009535642A (ja) 2006-05-03 2009-10-01 ゲイシンガー クリニック 非アルコール性脂肪性肝炎（ｎａｓｈ）を診断及び予測する方法
US20100028319A1 (en) 2007-02-02 2010-02-04 Kaneka Corporation Composition for prevention or treatment of diabetes
AR069500A1 (es) * 2007-11-30 2010-01-27 Univ California Metodos de tratamiento de la esteatohepatitis no alcoholica (nash ) utilizando productos de cisteamina

Also Published As

Publication number Publication date
JP2014237670A (ja) 2014-12-18
EP2636404A3 (en) 2013-10-16
CN101932238B (zh) 2015-04-08
CL2008003582A1 (es) 2009-04-03
PL2214480T3 (pl) 2013-11-29
RU2010126631A (ru) 2012-01-10
BRPI0819690A2 (pt) 2014-10-07
US20100303870A1 (en) 2010-12-02
MX2010005921A (es) 2010-06-11
CA2706768C (en) 2016-06-28
AU2008329628A1 (en) 2009-06-04
CA2706768A1 (en) 2009-06-04
TWI535435B (zh) 2016-06-01
TW200927093A (en) 2009-07-01
TWI478710B (zh) 2015-04-01
MY156316A (en) 2016-02-11
US20120015005A1 (en) 2012-01-19
SG10201403200RA (en) 2014-10-30
IL205909B (en) 2018-05-31
BRPI0819690B8 (pt) 2021-05-25
JP6121951B2 (ja) 2017-04-26
EP2214480A1 (en) 2010-08-11
US7994226B2 (en) 2011-08-09
EP2636404A2 (en) 2013-09-11
CN101932238A (zh) 2010-12-29
AU2008329628B2 (en) 2014-06-26
BRPI0819690B1 (pt) 2019-07-30
NZ585732A (en) 2012-02-24
JP2011505375A (ja) 2011-02-24
EP2214480A4 (en) 2010-09-29
EP2636404B1 (en) 2019-03-20
CN104825430A (zh) 2015-08-12
CN104825430B (zh) 2018-05-04
RU2498795C2 (ru) 2013-11-20
US8263662B2 (en) 2012-09-11
US20170304233A1 (en) 2017-10-26
WO2009070781A1 (en) 2009-06-04
DK2214480T3 (da) 2013-07-08
KR20100091219A (ko) 2010-08-18
JP5583022B2 (ja) 2014-09-03
TW201513855A (zh) 2015-04-16
CY1114126T1 (el) 2016-07-27
US20130183351A1 (en) 2013-07-18
MX360827B (es) 2018-11-16
HK1141945A1 (en) 2010-11-26
ES2417179T3 (es) 2013-08-06
EP2214480B1 (en) 2013-03-27
US9511038B2 (en) 2016-12-06
JP2017165735A (ja) 2017-09-21
ZA201003670B (en) 2011-08-31
US20160143865A1 (en) 2016-05-26
PT2214480E (pt) 2013-07-23
US9149448B2 (en) 2015-10-06
HRP20130590T1 (en) 2013-08-31
US10307386B2 (en) 2019-06-04
IL205909A0 (en) 2010-11-30
IL254586A0 (en) 2017-11-30

Similar Documents

Publication Publication Date Title
AR069500A1 (es) Metodos de tratamiento de la esteatohepatitis no alcoholica (nash ) utilizando productos de cisteamina
EA023971B1 (ru) Применение композиции, содержащей покрытые энтеросолюбильной оболочкой цистамин или цистеамин, для лечения цистиноза и способ лечения цистиноза
JP2017128614A5 (es)
CA2868362C (en) Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix
JP2013522219A5 (es)
ES2104044T3 (es) Capsulas blandas revestidas entericas y metodo para su produccion.
HRP20230305T1 (hr) Pripravci za ileo-jejunalnu dostavu lijeka
CA2403670A1 (en) Multiparticulate drug form comprising at least two differently coated pellet forms
SG10201400685SA (en) Use Of Eicosapentaenoic Acid Ethyl Ester For Treating Hypertriglyceridemia
EA201390981A1 (ru) Разрушающаяся во рту таблетка
WO2008044236B1 (en) Improved release of statins in the intestine
JP2015506359A5 (es)
RU2014127884A (ru) Способы лечения сердечно-сосудистого нарушения
CA2797812A1 (en) Enteric tablet
MX2013014142A (es) Composicion farmaceutica o nutraceutica de resistencia gastrica con resistencia contra la influenza de etanol.
TW201740932A (zh) 美沙拉 的口服醫藥組成物
JP2009505991A5 (es)
HRP20211269T1 (hr) Kompozicije prolijeka na bazi monometil fumarata
KR102352729B1 (ko) 간 질환의 치료 방법
RU2011110756A (ru) Фармацевтическая композиция в виде разовой пероральной дозы, содержащая леводопу, карбидопу и энтакапон, или их соли
JP2019513801A5 (es)
RU2016115985A (ru) Лактоферрин для лечения ibd, вызванного бактериальной инвазией
CN107088190A (zh) 富马酸酯在制备治疗肝病药物中的应用
CA2797809A1 (en) Enteric tablet
CN101708169A (zh) 一种含丹皮酚活性物质的结肠靶向给药制剂及其制备方法

Legal Events

Date Code Title Description
FB Suspension of granting procedure